Article
Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Cancer science - 1 Aug 2016
Banno Eri, Togashi Yosuke, Nakamura Yu, Chiba Masato, Kobayashi Yoshihisa, Hayashi Hidetoshi, Terashima Masato, de Velasco Marco A, Sakai Kazuko, Fujita Yoshihiko, Mitsudomi Tetsuya, Nishio Kazuto
Abstract excerpt
Most patients with non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations, such as deletions in exon 19 or the L858R mutation in exon 21, respond dramatically to EGFR tyrosine kinase inhibitors (EGFR-TKI), and their sensitivities to various EGFR-TKI have been well characterized. Our previous article showed the in vitro sensitivities of EGFR exon 18 mutations to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.